HER2 저해제 시장 규모, 점유율 및 성장 분석 : 약제 유형별, 용도별, 투여 경로별, 지역별 - 업계 예측(2026-2033년)

Global HER2 Inhibitors Market size was valued at USD 10.14 Billion in 2024 and is poised to grow from USD 11.17 Billion in 2025 to USD 24.3 Billion by 2033, growing at a CAGR of 10.2% during the forecast period (2026-2033).

The escalating prevalence of breast and gastric cancers, particularly HER2-positive variants, has significantly heightened the demand for HER2 inhibitors, crucial in targeted oncology therapies. These aggressive cancers are associated with lower survival rates, propelling a shift towards precision treatments aimed at improving patient outcomes. Advances in diagnostic methods, such as immunohistochemistry and fluorescence in situ hybridization, are enhancing early detection capabilities and broadening the application of HER2 inhibitors. Additionally, the introduction of innovative antibody-drug conjugates and biosimilars is driving down costs, thereby improving global access to vital care. Regulatory support from key health authorities is further accelerating the clinical development of HER2-targeted therapies, making them central to oncology portfolios, fostering market growth, and spurring ongoing innovation in HER2 treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HER2 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HER2 Inhibitors Market Segments Analysis

Global HER2 Inhibitors Market is segmented by Treatment, Application, End User and region. Based on Treatment, the market is segmented into Monotherapy and Combination Therapy. Based on Application, the market is segmented into Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer and Other Applications. Based on End User, the market is segmented into Hospitals, Clinics and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HER2 Inhibitors Market

The increasing incidence of HER2-positive cancers, particularly in breast and gastric forms, serves as a significant catalyst for the HER2 inhibitors market. Enhanced awareness, education, and advancements in diagnostic technologies are leading to more cases being identified at earlier stages, resulting in a larger patient cohort requiring HER2-targeted therapies. This rising demand is driving the expansion of the global HER2 inhibitors market, as healthcare systems are compelled to upgrade their offerings to meet the needs of these patients. Consequently, the combination of higher detection rates and an expanding patient population is fueling the ongoing growth in this sector.

Restraints in the Global HER2 Inhibitors Market

The global HER2 inhibitors market faces significant challenges due to the high costs associated with these treatments, which create barriers to access, especially in low- and middle-income countries. The financial burden imposed on healthcare systems and patients alike restricts the availability of these essential therapies, hindering broader adoption and equitable access to advanced cancer care. This economic limitation not only stifles market growth but also perpetuates disparities in treatment options, ultimately impacting patient outcomes and the overall effectiveness of oncology advancements across various regions. Addressing these cost-related constraints is crucial for enhancing accessibility to these vital medications.

Market Trends of the Global HER2 Inhibitors Market

The global HER2 inhibitors market is witnessing significant growth driven by innovations in targeted therapy and personalized medicine. The development of novel HER2 inhibitors with enhanced specificity and potency is enhancing treatment efficacy for patients with HER2-positive cancers. This tailored approach not only improves clinical outcomes but also minimizes adverse effects, making therapies more tolerable for patients. As healthcare providers continue to embrace precision medicine, the demand for these advanced inhibitors is expected to rise, reflecting a broader trend toward individualized treatment regimens in oncology that prioritize both efficacy and safety in cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global HER2 Inhibitors Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Monotherapy
  • Single-Agent HER2 Inhibitors
  • Targeted HER2 Therapies
• Combination Therapy
  • HER2 Inhibitors Combined With Chemotherapy
  • HER2 Inhibitors Combined With Targeted Therapies
  • HER2 Inhibitors Combined With Hormonal Therapies

Global HER2 Inhibitors Market Size by Application & CAGR (2026-2033)

• Market Overview
• Squamous Cell Carcinoma
• Adenocarcinoma
• Large Cell Carcinoma
• Breast Cancer
• Other Applications

Global HER2 Inhibitors Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Other End Users

Global HER2 Inhibitors Market Size & CAGR (2026-2033)

• North America (Treatment, Application, End User)
  • US
  • Canada
• Europe (Treatment, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Genentech (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Symbio Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Puma Biotechnology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipca Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations